荆花胃康胶丸联合PPI三联治疗幽门螺杆菌阳性80例

摘要

目的:观察荆花胃康胶丸联合PPI三联治疗幽门螺杆菌(Hp)感染的疗效.方法:将在本院就诊,经14C,13C尿素呼气试验确诊为Hp阳性的患者80例,随机分为两组:①治疗组即荆花胃康组(40例):兰索拉唑+呋喃唑酮+克拉霉素分散片+荆花胃康胶丸,bid,疗程7d.②三联对照组(40例):兰索拉唑+呋喃唑酮+克拉霉素分散片,bid,疗程7d.分别于治疗后7d和30d观察临床症状的缓解程度.疗程结束后4周进行14C或13C尿素呼气试验检测Hp.结果:Hp阳性患者中,荆花胃康组和三联对照组的Hp根除率分别为92.5％和62.5％,差异有显著学显著性,并且在治疗后患者嗳气、上腹胀及上腹痛等临床症状缓解方面,荆花胃康组明显优于三联对照组(P＜0.05).结论:荆花胃康胶丸联合PPI三联在Hp根除率方面与传统三联法相比明显升高,且在治疗后临床症状缓解方面治疗组优于对照组.%Objective; To observe the effect of JinghuaWeikang capsule and PPI trilogy on the treatment of Helicobacter pylori infection. Methods; 80 patients diagnosised with Helicobacter pylori infection by pathology or 14C or C breath test were randomly divided into the trial group and the control group. The trial group was treated with lansoprazole, Furazolidone, Clarithromycin and JinghuaWeikang Capsule, twice a day; and the control group were treated with lansoprazole. Furazolidone and Clarithromycin twice a day, the time of therapy in both two groups was 7 days. The therapy effects were observed at the 7 th day, 30th day after treatment and the patients were carried out the C or C breath test at the 4th week afer treatment. Results; Among the patients with Helicobacter pylori infection , the eradicating rate in the trial group was 92. 5% and 62. 5% in the control group ( P < 0. 05 ). The effect of relieving symptoms including abdominal pain, belching and abdominal distension in the trial group was significantly superior to those in the control group. Conclusion; JinghuaWeikang capsule combined with the trilogy is better than single trilogy both in eradicating Helicobacter pylori infection and relieving symptoms including abdominal pain, belching and abdominal distension.